Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q SummaryTradingView·Aug 5 at 09:41 AMMCRB+2.19%
Seres Q2 2026 Earnings: A $25 Million VOWST Gain Drives Quarterly ProfitTradingKey·Aug 5 at 06:51 AMMCRB+2.19%
Seres Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 736 KEarnings Watch·Aug 5 at 06:06 AMMCRB+2.19%
Seres Therapeutics explores partnerships to advance SER-155 development in immune checkpoint inhibitor-related enterocolitisPUBT·Jul 8 at 07:02 AMMCRB+2.19%
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer TreatmentUnusual Whales·Jul 8 at 06:02 AMMCRB+2.19%
Seres reports early data showing SER-155 eases ICI-related enterocolitis without systemic immunosuppressives in MSK trialPUBT·Jul 8 at 06:02 AMMCRB+2.19%
